Thermography Cannot Be Recommended for Clinical Breast Cancer Screening
Thermography should not be used as a primary or adjunctive screening tool for breast cancer in clinical practice, as major guideline organizations do not endorse it and the FDA explicitly states it should not replace mammography. 1, 2
Guideline Position: Clear Rejection
The U.S. Preventive Services Task Force (USPSTF), American College of Physicians (ACP), and Canadian Task Force on Preventive Health Care have comprehensively reviewed breast cancer screening modalities and none recommend thermography 1, 2. These guidelines focus exclusively on mammography as the primary screening method, with specific discussions of emerging technologies like digital breast tomosynthesis (DBT), MRI, and ultrasound—but thermography is notably absent from consideration as a viable option.
The FDA has explicitly stated that thermography should not be used in place of mammography for breast cancer screening or diagnosis 3. This regulatory position reflects the lack of sufficient evidence to support its clinical use.
Literature Review: Performance Across Technologies
Diagnostic Accuracy Studies
The evidence on thermography shows highly variable and generally inadequate performance:
Sensitivity ranges dramatically from 25% to 97%, with specificity ranging from 12% to 85% when compared to histology as the gold standard 4. This extreme variability reflects fundamental problems with standardization, interpretation criteria, and study methodology.
A 2024 systematic review and meta-analysis found pooled sensitivity of 88.5% and specificity of 71.8%, but with extremely high heterogeneity (I² values of 79.3% and 99.1% respectively) 5. This heterogeneity indicates that results are not reproducible across different settings, equipment, or patient populations.
Head-to-Head Comparisons with Mammography
When directly compared to mammography:
- As a screening tool: Thermography showed only 25% sensitivity versus mammography's standard performance, with 74% specificity 4
- As a diagnostic tool: One 2026 study found thermography detected 18 of 24 malignant lesions (75% sensitivity) compared to mammography's 23 of 24 (95.8% sensitivity) 6
- A 2016 pilot study reported 92.31% sensitivity for thermography versus 95.38% for mammography, but this was in a highly selected population of already-confirmed cancer cases 7
Vendor-Specific Technologies
The literature includes various thermographic approaches:
Infrared thermography (non-contact): Most commonly studied, using thermal cameras to detect temperature differences. Studies show wide performance variation 6, 8, 9
Liquid Crystal Thermography (LCT): Contact-based method using thermochromic foils (e.g., Braster system). A 2026 review concluded that evidence is insufficient to establish LCT as a standalone substitute for mammography, with the FDA explicitly stating it should not replace mammography 3
Computer-aided detection systems: A 2021 study claimed 96.57% classification accuracy for thermography versus 98.11% for mammography, but this was in a highly artificial experimental setting, not real-world screening 10
Critical Methodological Flaws
The thermography literature suffers from severe limitations that invalidate most positive findings:
- Spectrum bias: Most studies recruit only patients with confirmed cancer or suspicious masses requiring biopsy, not true screening populations 5
- Small sample sizes: The majority of studies include fewer than 100 patients 4, 5
- Lack of standardization: No consensus exists on imaging protocols, temperature thresholds, interpretation criteria, or equipment specifications 3, 5
- Publication bias: Studies showing positive results are more likely to be published
- Verification bias: Not all patients receive the same reference standard testing
Common Pitfalls and Confounding Factors
Thermographic interpretation is plagued by numerous confounders:
- Physiological variations: Menstrual cycle, ambient temperature, recent physical activity, caffeine intake, and time of day all affect breast temperature 3
- Dense breast tissue: Despite claims that thermography performs better in dense breasts, no published comparative study has provided head-to-head false-negative and false-positive counts across modalities within this subgroup 3
- Lack of specialized training: There is a shortage of radiologists trained in thermographic interpretation 9
- Equipment variability: Different thermal cameras and processing algorithms yield inconsistent results
Why Thermography Fails as a Screening Tool
The fundamental problem is inadequate sensitivity. A screening test that misses 25-75% of cancers (depending on the study) is clinically unacceptable. The 2012 systematic review found only 25% sensitivity in screening populations 4, meaning three-quarters of cancers would be missed.
Even the most optimistic recent studies show thermography performing worse than mammography, which itself has known limitations. The USPSTF guidelines establish that mammography reduces breast cancer mortality with moderate to substantial benefit in women aged 50-74 years 1. No such mortality benefit has ever been demonstrated for thermography.
Analysis and Conclusion
Thermography cannot be recommended for clinical breast cancer screening based on current evidence. The performance characteristics are inadequate, the methodology is unstandardized, and no major medical organization endorses its use. While some recent studies with machine learning algorithms show improved results, these are experimental and have not been validated in real-world screening populations.
The claims that thermography is particularly useful in dense breasts, young women, or resource-limited settings are not supported by rigorous comparative data 3. The fact that it is radiation-free and potentially less expensive does not compensate for missing the majority of cancers in screening populations.
For clinical practice: Continue using mammography as the primary screening modality per USPSTF guidelines (biennial screening for women aged 50-74 years, individualized decision-making for ages 40-49) 1. Do not offer thermography as an alternative or adjunct to mammography. If patients inquire about thermography, clearly explain that it is not FDA-approved for breast cancer screening and that major medical organizations do not recommend it.
For future research: Before thermography could be reconsidered, large prospective studies (>1000 participants) in true screening populations with standardized protocols, blinded interpretation, and long-term follow-up for interval cancers and mortality outcomes would be required. Until such evidence exists, thermography remains an investigational technology without clinical utility.